Fredun Pharmaceuticals Launches Premium Wellness Brand 'DAULCÉL' Focused on Cellular Longevity and Preventive Healthcare
Published on: May 16, 2026, 1:21 a.m. | Source: scanx.trade
Fredun Pharmaceuticals Limited launched 'DAULCÉL' on May 15, 2026, a premium wellness brand focused on cellular longevity, NAD+ science, and preventive healthcare, marking the company's strategic entry into India's emerging longevity and wellness segment. The brand is positioned as India's first premium NAD+-based wellness offering, complementing the company's existing pharmaceutical capabilities. In FY25, Fredun reported total revenues of ₹ 456 Cr, EBITDA of ₹ 55 Cr, and a PAT of ₹ 21 Cr.
